Osivax has changed course on OVX836 after the influenza A vaccine failed a phase 2b study in 2,850 healthy adults in Europe. The company said the shot delivered vaccine efficacy of 24%, well short of the 50% required to meet the trial’s primary endpoint.
That outcome pushes OVX836 away from a stand-alone positioning and toward a combination role. The strategic shift matters because Osivax is no longer arguing that a nucleoprotein-based vaccine can displace conventional seasonal influenza vaccines on its own. Instead, it is framing OVX836 as a way to add broader immunity to existing products built around surface antigens.
The Data
OVX836 is designed to target the influenza nucleoprotein, a highly conserved internal antigen. Osivax said the study did not meet its primary goal, but it highlighted what it described as an emerging pattern for a preliminary vaccine-efficacy signal across secondary measures.
Specifically, the company pointed to an estimated CDC-defined influenza-like illness and strain-specific vaccine efficacy of 28%, plus vaccine efficacies of 27% and 25%, respectively, for the influenza A/H3 and A/H1N1pdm09 strains. Osivax also said OVX836 showed a favorable safety profile consistent with previous clinical trials and induced robust NP-specific antibody and T-cell responses.
The company went further, saying these findings represent, to its knowledge, the first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes in a field efficacy trial. That is a narrower claim than clinical success, but it preserves the scientific rationale for the program after the miss.
The Strategic Reset
Osivax is now focusing on combination development. In August, the company secured a non-exclusive license to GC Biopharma’s inactivated seasonal influenza vaccine, GC FLU, which is approved in South Korea. GC FLU is designed to trigger antibody responses against hemagglutinin surface antigens from A and B forms of the flu virus.
Osivax’s plan is to combine GC FLU with OVX836 in a single vaccine. The logic is that traditional seasonal shots target surface proteins that change over time, forcing seasonal updates and still only partly matching circulating strains. OVX836’s intended role is to add broader cellular immunity against influenza A through the more conserved nucleoprotein.
That combination approach is not entirely theoretical for Osivax. The company previously reported phase 2a evidence from a 60-volunteer study combining OVX836 with GSK’s Fluarix Tetra, and said it came away believing synergistic immune responses and broader cross-protection could make the regimen more effective than current monotherapy vaccines. Osivax has also tested a combination in a larger phase 2 study. Another possible path is a pairing with a vaccine from a second, undisclosed global pharmaceutical partner.
The signal from this readout is less about near-term efficacy and more about product definition. A 24% monotherapy result does not support a replacement-vaccine thesis, but it may still support a platform thesis if Osivax can show that adding OVX836 meaningfully broadens or durably strengthens protection when layered onto standard seasonal vaccines.
